Get to know D.C. with our daily newsletter
We dive deep on the day’s biggest story and share links to everything you need to know.
Get the free newsletter Success! You re on the list. Whoops! There was an error and we couldn t process your subscription. Please reload the page and try again. Processing…
I already get the newsletter
The COVID-19 pandemic forced people around the world to instantly change the way they lived their lives: how they bought groceries, how they traveled, and if and how they worked. Elected officials on the local and national level responded with financial resources, rent and utility assistance programs, emergency housing for those experiencing homelessness, and initiatives that gave residents staying closer to home more use of their streets. Neighbors got to work as well: They organized mutual aid groups, helped one another book vaccination appointments, and offered helping hands. The past 14 months have by no
Is Denali Therapeutics Inc. (DNLI) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Denali Therapeutics Inc. (NASDAQ: DNLI), and shared their insights on the company. Denali Therapeutics Inc. is a South San Francisco, California-based biotechnology company that currently has a $7.4 billion market capitalization. Since the beginning of the year, DNLI delivered a -26.79% return, while its 12-month gains are up by 181.28%. As of April 29, 2021, the stock closed at $61.32 per shar
Baron Funds on ICON Public Ltd Co. (ICLR): “We See Significant Upside in the Stock Price”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned ICON Public Limited Company (NASDAQ: ICLR), and shared their insights on the company. ICON Public Limited Company is a Dublin, Ireland-based medical device company that currently has an $11.3 billion market capitalization. Since the beginning of the year, ICLR delivered a 9.63% return, extending its 12-month gains to 38.66%. As of April 29, 2021, the stock cl
Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned BridgeBio Pharma, Inc. (NASDAQ: BBIO), and shared their insights on the company. BridgeBio Pharma, Inc. is a Palo Alto, California-based biotechnology company that currently has an $8.3 billion market capitalization. Since the beginning of the year, BBIO delivered a -20.69% return, while its 12-month gains are up by 94.68%. As of April 29, 2021, the stock closed at $55.27 per share.